April 19, 2018 Affymetrix releases complete genotyping data place on its website Affymetrix, Inc. today announced the launch of a total data set of 5 million variants on its internet site. The data set contains genotyping data for a lot more than 2 million validated uncommon and common genomic variants that Affymetrix lately contributed to the 1000 Genomes Project, many of which were not previously obtainable from any source nizagara . The data will be incorporated in to the 1000 Genomes Project’s public data repository. With the option of millions of novel markers in more diverse populations, combined with the increasing capacity of our microarray technology, we are providing experts with more resources to accelerate their disease association research, said Kevin King, President and CEO of Affymetrix. Related StoriesEntirely new enzymatic procedure for DNA synthesisResearchers reveal how charged gold nanoparticles influence structure of DNA and RNADisclosing genetic risk for CHD results in lower low-density lipoprotein cholesterol This clearance is first-of-its-kind, and represents a revolution in molecular genetic testing. CytoScan Dx Assay is the first FDA-cleared check that analyzes the whole genome in a single assay at unprecedented resolution, which significantly improves diagnostic capability. Developing and clearing this assay create Affymetrix as a head in advancing molecular diagnostics by getting high quality genomic equipment into routine software in the clinic, said Frank Witney, President and CEO of Affymetrix. We expect to be making CytoScan Dx Assay available to laboratories within the US in the next few months.